Table 3 Clinical characteristics of the patients at last observation
Clinical characteristics at the last follow-up | All 53 patients | 43 Patients who did not develop renal flare | 10 Patients who developed renal flare |
|---|---|---|---|
Follow-up months | 60.69 (37.20–78.70 | 63.56 (44.13–80.87) | 28.19(24.83–39.38) |
Serum creatinine (mg/dL) | 0.80 (0.68–0.95) | 0.77 (0.66–0.89) | 0.89 (0.81–0.95) |
eGFR (mL/min/1.73 m²) | 93.52 (79.47-107.56) | 95.94 (84.80-108.39) | 89.39 (79.42–93.61) |
Proteinuria (g/24 h) | 0.12 (0.09–0.26) | 0.12 (0.08–0.26) | 0.22 (0.12–0.48) |
Arterial hypertension | 27 (50.9) | 21 (39.6) | 6 (11.3) |
Red Blood cells /ul | 4465 (4095–4782) | 4535 (4130-4842.5) | 4395 (4032.5–4570) |
C3 (mg/dl) | 86 (75–105) | 86 (76–106) | 78.50 (65-94.25) |
C4 (mg/dl) | 14 (10–21) | 15 (11–21) | 11 (8-15.50) |
Anti-DNA antibodies IU/mL | 35 (10-89.5) | 28 (9.83–71.28) | 74.90 (36.5–184) |
Anti.C1q antibodies UA | 19 (10–42) | 17 (9.5-30.75) | 33 (25.55–55.5) |
Hydroxychloroquine n. (%) | 46 (86.79) | 40 (93.02) | 6 (60%) |
Prednisone mg/day | 5(2.5-5) | 5(2.5-5) | 5(5–5) |
NO IS/Aza/CsA/MMF/belimumab n. (%) | 1 (1.9)/ 4 (7.5) /1 (1.9)/47* (88.8) | 0 (2.3)/4 (9.3)/1 (2.3)/37 (86%)** | 0/0/0/10 (100) *** |
Complete/partial remission/CKD/ PALN | 45 (84.9%)/4 (7.5%)/3 (5.7%)/ 1(1.9) | 37 (86.04)/2 (4.6), 2(4.6)/1 (2.3) | 7/2/1 |
Death | 1 | 1 | 0 |